Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer

Drugs Aging. 2012 Mar 1;29(3):243-248. doi: 10.2165/11209160-000000000-00000.

Abstract

Oral abiraterone acetate (Zytiga®), a selective cytochrome P450 17A1 enzyme inhibitor, is used in combination with prednisone or prednisolone to treat patients with metastatic castration-resistant prostate cancer (CRPC) who have previously received docetaxel-containing chemotherapy. In a clinical trial in patients with CRPC, abiraterone acetate plus prednisone significantly prolonged overall survival, the time to prostate-specific antigen progression and progression-free survival compared with placebo plus prednisone.

MeSH terms

  • Abiraterone Acetate
  • Androstadienes / adverse effects
  • Androstadienes / pharmacology
  • Androstadienes / therapeutic use*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Enzyme Inhibitors / adverse effects
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use*
  • Humans
  • Male
  • Prostatic Neoplasms / drug therapy*
  • Steroid 17-alpha-Hydroxylase / antagonists & inhibitors*

Substances

  • Androstadienes
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • CYP17A1 protein, human
  • Steroid 17-alpha-Hydroxylase
  • Abiraterone Acetate